Viracta Therapeutics, Inc. – NASDAQ:VIRX
Viracta Therapeutics stock price today
$0.01
-0.15
-93.89%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Viracta Therapeutics stock price monthly change
-70.26%
month
Viracta Therapeutics stock price quarterly change
-70.26%
quarter
Viracta Therapeutics stock price yearly change
-72.00%
year
Viracta Therapeutics key metrics
Market Cap | 8.76M |
Enterprise value | 43.17M |
P/E | -1.18 |
EV/Sales | N/A |
EV/EBITDA | -0.88 |
Price/Sales | N/A |
Price/Book | 0.89 |
PEG ratio | 2.37 |
EPS | -1.23 |
Revenue | N/A |
EBITDA | -52.12M |
Income | -47.99M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeViracta Therapeutics stock price history
Viracta Therapeutics stock forecast
Viracta Therapeutics financial statements
| Jun 2023 | 0 | -12.48M | |
|---|---|---|---|
| Sep 2023 | 0 | -12.6M | |
| Dec 2023 | 738K | -13.76M | -1865.18% |
| Mar 2024 | 0 | -9.14M |
| Dec 2023 | 738K | -13.76M | -1865.18% |
|---|---|---|---|
| Mar 2024 | 0 | -9.14M | |
| Oct 2025 | 0 | -10.22M | |
| Dec 2025 | 0 | -10.61M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 76859000 | 36.07M | 46.94% |
|---|---|---|---|
| Sep 2023 | 66437000 | 36.42M | 54.83% |
| Dec 2023 | 56692000 | 38.37M | 67.69% |
| Mar 2024 | 41334000 | 30.25M | 73.19% |
| Jun 2023 | -7.99M | 3.98M | 204K |
|---|---|---|---|
| Sep 2023 | -10.53M | 9.09M | 0 |
| Dec 2023 | -10.02M | 9.27M | 218K |
| Mar 2024 | -7.84M | 14.19M | -6.59M |
Viracta Therapeutics alternative data
| Aug 2023 | 39 |
|---|---|
| Sep 2023 | 41 |
| Oct 2023 | 41 |
| Nov 2023 | 41 |
| Dec 2023 | 41 |
| Jan 2024 | 41 |
| Feb 2024 | 41 |
| Mar 2024 | 40 |
| Apr 2024 | 40 |
| May 2024 | 40 |
| Jun 2024 | 40 |
| Jul 2024 | 40 |
Viracta Therapeutics other data
8.55%
-24.40%
of VIRX is owned by hedge funds
27
-26
3.23M
-9.13M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 0 | 3635 |
| Aug 2023 | 0 | 3512 |
| Nov 2023 | 52094 | 3720 |
| Dec 2023 | 47906 | 0 |
| Feb 2024 | 0 | 3405 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | ROYSTON IVOR director | Common Stock | 25,219 | N/A | N/A | ||
Option | ROYSTON IVOR director | Restricted Stock Units | 25,219 | N/A | N/A | ||
Option | POMERANTZ ROGER director | Common Stock | 9,034 | N/A | N/A | ||
Option | POMERANTZ ROGER director | Restricted Stock Units | 9,034 | N/A | N/A | ||
Option | ROYSTON IVOR director | Common Stock | 25,219 | N/A | N/A | ||
Option | ROYSTON IVOR director | Restricted Stock Units | 25,219 | N/A | N/A | ||
Option | POMERANTZ ROGER director | Common Stock | 9,034 | N/A | N/A | ||
Option | POMERANTZ ROGER director | Restricted Stock Units | 9,034 | N/A | N/A | ||
Option | POMERANTZ ROGER director | Common Stock | 9,035 | N/A | N/A | ||
Option | POMERANTZ ROGER director | Restricted Stock Units | 9,035 | N/A | N/A |
| Patent |
|---|
Application Filling date: 8 Dec 2021 Issue date: 11 Aug 2022 |
Application Filling date: 18 Jan 2022 Issue date: 5 May 2022 |
Grant Filling date: 8 Jul 2020 Issue date: 23 Mar 2021 |
Grant Filling date: 23 Apr 2018 Issue date: 8 Dec 2020 |
Application Filling date: 8 Jul 2020 Issue date: 3 Dec 2020 |
Application Filling date: 11 Jan 2019 Issue date: 26 Nov 2020 |
Application Filling date: 14 Jul 2017 Issue date: 26 Sep 2019 |
-
What's the price of Viracta Therapeutics stock today?
One share of Viracta Therapeutics stock can currently be purchased for approximately $0.01.
-
When is Viracta Therapeutics's next earnings date?
Unfortunately, Viracta Therapeutics's (VIRX) next earnings date is currently unknown.
-
Does Viracta Therapeutics pay dividends?
No, Viracta Therapeutics does not pay dividends.
-
How much money does Viracta Therapeutics make?
Viracta Therapeutics has a market capitalization of 8.76M.
-
What is Viracta Therapeutics's stock symbol?
Viracta Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VIRX".
-
What is Viracta Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Viracta Therapeutics?
Shares of Viracta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Viracta Therapeutics's key executives?
Viracta Therapeutics's management team includes the following people:
- Dr. Lisa Rojkjaer Chief Medical Officer(age: 59, pay: $463,700)
- Dr. Ivor Royston M.D. Chief Executive Officer, Pres & Director(age: 79, pay: $456,750)
- Mr. Daniel R. Chevallard Chief Financial Officer, Chief Operating Officer & Sec.(age: 45, pay: $418,250)
-
How many employees does Viracta Therapeutics have?
As Jul 2024, Viracta Therapeutics employs 40 workers.
-
When Viracta Therapeutics went public?
Viracta Therapeutics, Inc. is publicly traded company for more then 19 years since IPO on 27 Sep 2005.
-
What is Viracta Therapeutics's official website?
The official website for Viracta Therapeutics is viracta.com.
-
Where are Viracta Therapeutics's headquarters?
Viracta Therapeutics is headquartered at 2533 South Coast Highway 101, Cardiff-by-the-Sea, CA.
-
How can i contact Viracta Therapeutics?
Viracta Therapeutics's mailing address is 2533 South Coast Highway 101, Cardiff-by-the-Sea, CA and company can be reached via phone at 858 400 8470.
Viracta Therapeutics company profile:
Viracta Therapeutics, Inc.
viracta.comExchange:
NASDAQ
Full time employees:
40
Industry:
Biotechnology
Sector:
Healthcare
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
2533 South Coast Highway 101
Cardiff-by-the-Sea, CA 92007
Cardiff-by-the-Sea, CA 92007
CIK: 0001061027
ISIN: US92765F1084
CUSIP: 92765F108
